Patents by Inventor CESAR ADOLFO SOMMER
CESAR ADOLFO SOMMER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912776Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: March 15, 2022Date of Patent: February 27, 2024Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Publication number: 20240042030Abstract: Provided herein are engineered immune cells and populations thereof for administration to subjects to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced level of one or more of CD48, CD58, ICAM-1, RFX5, NLRC5, TAP2, ?2m, TRAC, RFXAP, CIITA and RFXANK. The cells optionally are further engineered to express one or more than one additional protein such as an antigen binding protein (e.g., a chimeric antigen receptor (CAR) or T cell receptor) and/or a CD70 binding protein to target tumor cells or other damaged cells in the subject and/or to express other genes at a reduced level. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering the cells and the compositions.Type: ApplicationFiled: July 28, 2023Publication date: February 8, 2024Inventors: Cesar Adolfo SOMMER, Hsin-Yuan CHENG, Barbra Johnson SASU
-
Publication number: 20230181634Abstract: Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).Type: ApplicationFiled: May 31, 2018Publication date: June 15, 2023Inventors: Barbra Johnson SASU, Danielle Elizabeth DETTLING, Cesar Adolfo SOMMER, Yik Andy YEUNG, Moustafa Marc HAMZE
-
Publication number: 20230112444Abstract: Provided herein are BCMA CARs and CAR-T cells, gamma secretase inhibitors, and the combination thereof. Also provided are the combination of BCMA CAR-T cells and gamma secretase inhibitors for use in treating cancer. In some embodiments, particular dosing regimens, redosing regimens, and combination regimens with lymphodepletion are provided, for the treatment and clinical management of multiple myeloma in subjects in need thereof.Type: ApplicationFiled: January 15, 2021Publication date: April 13, 2023Applicant: SpringWorks Therapeutics, Inc.Inventors: Arun BALAKUMARAN, Cesar Adolfo SOMMER, Trevor Michael BENTLEY, Todd Webster SHEARER, Lesley Mary SMITH
-
Publication number: 20230059489Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).Type: ApplicationFiled: June 24, 2022Publication date: February 23, 2023Inventors: Danielle Elizabeth DETTLING, Yik Andy YEUNG, Kristian Todd POULSEN, Veena KRISHNAMOORTHY, Cesar Adolfo SOMMER
-
Publication number: 20220409665Abstract: Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.Type: ApplicationFiled: June 15, 2022Publication date: December 29, 2022Inventors: Elvin J. LAURON, Siler PANOWSKI, Barbra Johnson SASU, Cesar Adolfo SOMMER, Surabhi SRIVATSA SRINIVASAN, Thomas John VAN BLARCOM, Shanshan LANG
-
Publication number: 20220340671Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: ApplicationFiled: March 15, 2022Publication date: October 27, 2022Inventors: Tracy Chia-Chien KUO, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Publication number: 20220281950Abstract: Compositions, methods, expression vectors and engineered immune cells for improving therapies that entail the administration of allogeneic cells to a patient. An immune cell, e.g., a T cell, modified to comprise and/or express FasL protein or a FasL protein derivative from, for example, an expression vector comprising a polynucleotide that encodes FasL protein or a FasL protein derivative, and to express FasR at a reduced level, and further modified to comprise and/or express an antigen binding protein e.g., a chimeric antigen receptor (CAR). An improved method of CAR T-cell therapy that comprises administering the improved immune cells, and compositions that comprise the improved immune cells. Methods of improving persistence of administered cells and reducing activation-induced cell death comprising administering the improved cells.Type: ApplicationFiled: March 4, 2022Publication date: September 8, 2022Inventors: Michael Thomas BETHUNE, Eric Hans GSCHWENG, Thomas John VAN BLARCOM, Cesar Adolfo SOMMER
-
Patent number: 11421040Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).Type: GrantFiled: May 31, 2018Date of Patent: August 23, 2022Assignee: Pfizer Inc.Inventors: Danielle Elizabeth Dettling, Yik Andy Yeung, Kristian Todd Poulsen, Veena Krishnamoorthy, Cesar Adolfo Sommer
-
Publication number: 20220251505Abstract: Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced level of one or more of RFX5, NLRC5, TAP2, ?2m, TRAC, RFXAP, CIITA and RFXANK. The cells optionally are further engineered to express one or more than one additional protein such as an antigen binding protein (e.g., a chimeric antigen receptor (CAR) or T cell receptor) to target tumor cells or other damaged cells in the patient and/or to express other genes at a reduced level. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering the cells and the compositions.Type: ApplicationFiled: January 28, 2022Publication date: August 11, 2022Inventors: Michael Thomas BETHUNE, Eric Hans GSCHWENG, Thomas John VAN BLARCOM, Cesar Adolfo SOMMER, Michael C YI
-
Patent number: 11312782Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: April 15, 2019Date of Patent: April 26, 2022Assignee: Pfizer Inc.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Publication number: 20210260118Abstract: Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.Type: ApplicationFiled: February 24, 2021Publication date: August 26, 2021Inventors: Regina Junhui LIN, Siler PANOWSKI, Cesar Adolfo SOMMER, Thomas John VAN BLARCOM, Barbra Johnson SASU, Arun BALAKUMARAN
-
Publication number: 20190241669Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: ApplicationFiled: April 15, 2019Publication date: August 8, 2019Inventors: Tracy Chia-Chien KUO, Bijan Andre BOLDAJIPOUR, Javier Fernando CHAPARRO RIGGERS, Philippe DUCHATEAU, Roman Ariel GALETTO, Alexandre JUILLERAT, Thomas Charles PERTEL, Arvind RAJPAL, Barbra Johnson SASU, Cesar Adolfo SOMMER, Julien VALTON, Thomas John VAN BLARCOM
-
Patent number: 10294304Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: March 30, 2016Date of Patent: May 21, 2019Assignee: Pfizer Inc.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Publication number: 20180346601Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).Type: ApplicationFiled: May 31, 2018Publication date: December 6, 2018Applicant: PFIZER INC.Inventors: Danielle Elizabeth DETTLING, Yik Andy YEUNG, Kristian Todd POULSEN, Veena KRISHNAMOORTHY, Cesar Adolfo SOMMER
-
Publication number: 20160297884Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: ApplicationFiled: March 30, 2016Publication date: October 13, 2016Inventors: TRACY CHIA-CHIEN KUO, BIJAN ANDRE BOLDAJIPOUR, JAVIER FERNANDO CHAPARRO RIGGERS, PHILIPPE DUCHATEAU, ROMAN GALETTO, ALEXANDRE JUILLERAT, THOMAS CHARLES PERTEL, ARVIND RAJPAL, BARBRA JOHNSON SASU, CESAR ADOLFO SOMMER, JULIEN VALTON, THOMAS JOHN VAN BLARCOM